×
About 2,135 results

ALLMedicine™ Fibrosarcoma Center

Research & Reviews  755 results

COL1A1-PDGFB Fusion Associated Fibrosarcoma of the Uterine Corpus: A Case Report and Li...
https://doi.org/10.1097/PGP.0000000000000850
International Journal of Gynecological Pathology : Offici... Panwar V, Liu Y et. al.

Feb 3rd, 2023 - Uterine collagen type 1 alpha 1 (COL1A1) and platelet-derived growth factor beta chain (PDGFB) fusion associated fibrosarcoma is a recently described entity characterized by a specific translocation t(17;22) (q22;q13) leading to the formation of C...

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT03027388

Feb 1st, 2023 - Background: Primary gliomas are an incurable disease in spite of aggressive multimodality therapy consisting of craniotomy, irradiation, and chemotherapy. Therapeutic options for patients with recurrent glioma are limited, and there is an unmet ne...

Sequential chimeric fibula-gracilis flap to salvage a complex orbitomaxillary defect: A...
https://doi.org/10.1002/micr.31016
Microsurgery De Cicco D, Bottini GB et. al.

Jan 30th, 2023 - Extended maxillectomies with orbital exenteration and facial soft tissue resection need careful planning to achieve satisfactory functional and esthetic outcomes. Only a few solutions provide enough hard and soft tissue on a single pedicle, and on...

Molecular characterization of feline immune checkpoint molecules and establishment of P...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879432
PloS One; Maekawa N, Konnai S et. al.

Jan 27th, 2023 - Spontaneous tumors are a major cause of death in cats. Treatment of human tumors has progressed dramatically in the past decade, partly due to the success of immunotherapies using immune checkpoint inhibitors, such as anti-programmed death 1 (PD-1...

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
https://clinicaltrials.gov/ct2/show/NCT03834961

Jan 26th, 2023 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR) of children with infantile fibrosarcoma (IFS) treated with neoadjuvant larotrectinib prior to local control. SECONDARY OBJECTIVES: I. To determine event-free survival (EFS), over...

see more →

Guidelines  1 results

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatri...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903261
Current Oncology (Toronto, Ont.); Perreault S, Chami R et. al.

Jan 14th, 2021 - Neurotrophic tyrosine receptor kinase gene fusions (NTRK) are oncogenic drivers present at a low frequency in most tumour types (<5%), and at a higher frequency (>80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and cons...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  19 results

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT03027388

Feb 1st, 2023 - Background: Primary gliomas are an incurable disease in spite of aggressive multimodality therapy consisting of craniotomy, irradiation, and chemotherapy. Therapeutic options for patients with recurrent glioma are limited, and there is an unmet ne...

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
https://clinicaltrials.gov/ct2/show/NCT03834961

Jan 26th, 2023 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR) of children with infantile fibrosarcoma (IFS) treated with neoadjuvant larotrectinib prior to local control. SECONDARY OBJECTIVES: I. To determine event-free survival (EFS), over...

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
https://clinicaltrials.gov/ct2/show/NCT05221320

Jan 17th, 2023 - This is an open-label, multicenter, phase II basket study of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring rat sarcoma virus (RAS), a member of the rapidly accelerated fibrosar...

A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a...
https://clinicaltrials.gov/ct2/show/NCT05236257

Jan 12th, 2023 - This is an observational study in which data from the past of children and young people with a specific cancer, called NTRK gene fusion positive infantile fibrosarcoma (IFS) is studied. IFS is a rare type of childhood cancer that commonly affects ...

Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma
https://clinicaltrials.gov/ct2/show/NCT05525273

Jan 5th, 2023 - Background. Papillary craniopharyngioma harbours a BRAF mutation in 90% of cases. Treatment with BRAF + MEK (mitogen activated protein kinase ) inhibitors (dabrafenib + trametinib) may prevent patients from undergoing surgery with a high risk of s...

see more →

News  69 results

New Tissue-Agnostic Treatment Options Emerge
https://www.onclive.com/view/new-tissue-agnostic-treatment-options-emerge

Aug 2nd, 2022 - The menu of tissue-agnostic oncology drug approvals is growing, generating new treatment options for patients with rare cancers and strengthening the rationale for broad next-generation sequencing (NGS), experts say. In June 2022, the FDA approv...

Larotrectinib Shows Continued Tumor-Agnostic Efficacy in Pediatric TRK Fusion+ Cancer
https://www.onclive.com/view/larotrectinib-shows-continued-tumor-agnostic-efficacy-in-pediatric-trk-fusion-cancer

Jun 6th, 2022 - Pediatric patients with non–central nervous system (CNS), TRK fusion–positive cancers who were enrolled to the phase 1/2 SCOUT (NCT02637687) and phase 2 NAVIGATE (NCT02576431) trials and received larotrectinib (Vitrakvi) continued to experience ra...

RET and NTRK Inhibitors for Differentiated Thyroid Cancer
https://www.onclive.com/view/ret-and-ntrk-inhibitors-for-differentiated-thyroid-cancer

Jan 6th, 2022 - Lori Wirth, MD: Speaking of NTRK fusions, we have some great data to talk about with NTRK fusion-driven disease, RET fusion-driven disease. Maria, do you want to lead off on that discussion? Maria E. Cabanillas, MD: Sure. I think we could proba...

Putting the Extremely Rare Cardiac Angiosarcoma in the Spotlight
https://www.onclive.com/view/putting-the-extremely-rare-cardiac-angiosarcoma-in-the-spotlight

Dec 21st, 2021 - Cardiac angiosarcoma is an exceptionally rare cancer that has become national news because of the recent death of acclaimed fashion designer, Virgil Abloh. He was 41 years old when he died in November 2021, following a 2-year battle with the disea...

Clinical Management of NTRK+ Advanced NSCLC
https://www.onclive.com/view/clinical-management-of-ntrk-advanced-nsclc

Oct 12th, 2021 - Ben Levy, MD: There are now 2 TRK [tyrosine receptor kinase] inhibitors that are active, proven and FDA approved for TRK fusion-positive lung cancer. The first is larotrectinib. This was initially published in the New England Journal of Medicine l...

see more →

Patient Education  6 results see all →